BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 11506492)

  • 1. Neuroblastomas with chromosome 11q loss and single copy MYCN comprise a biologically distinct group of tumours with adverse prognosis.
    Luttikhuis ME; Powell JE; Rees SA; Genus T; Chughtai S; Ramani P; Mann JR; McConville CM
    Br J Cancer; 2001 Aug; 85(4):531-7. PubMed ID: 11506492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allelic deletion at 11q23 is common in MYCN single copy neuroblastomas.
    Guo C; White PS; Weiss MJ; Hogarty MD; Thompson PM; Stram DO; Gerbing R; Matthay KK; Seeger RC; Brodeur GM; Maris JM
    Oncogene; 1999 Sep; 18(35):4948-57. PubMed ID: 10490829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deletion of 11q23 is a frequent event in the evolution of MYCN single-copy high-risk neuroblastomas.
    Guo C; White PS; Hogarty MD; Brodeur GM; Gerbing R; Stram DO; Maris JM
    Med Pediatr Oncol; 2000 Dec; 35(6):544-6. PubMed ID: 11107113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative genomic hybridization (CGH) analysis of stage 4 neuroblastoma reveals high frequency of 11q deletion in tumors lacking MYCN amplification.
    Plantaz D; Vandesompele J; Van Roy N; Lastowska M; Bown N; Combaret V; Favrot MC; Delattre O; Michon J; Bénard J; Hartmann O; Nicholson JC; Ross FM; Brinkschmidt C; Laureys G; Caron H; Matthay KK; Feuerstein BG; Speleman F
    Int J Cancer; 2001 Mar; 91(5):680-6. PubMed ID: 11267980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allelic deletion at chromosome bands 11q14-23 is common in neuroblastoma.
    Maris JM; Guo C; White PS; Hogarty MD; Thompson PM; Stram DO; Gerbing R; Matthay KK; Seeger RC; Brodeur GM
    Med Pediatr Oncol; 2001 Jan; 36(1):24-7. PubMed ID: 11464895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FISH analyses for alterations in chromosomes 1, 2, 3, and 11 define high-risk groups in neuroblastoma.
    Spitz R; Hero B; Ernestus K; Berthold F
    Med Pediatr Oncol; 2003 Jul; 41(1):30-5. PubMed ID: 12764740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular cytogenetic characterization of two non-MYCN amplified neuroblastoma cell lines with complex t(11;17).
    McConville CM; Dyer S; Rees SA; Luttikhuis ME; McMullan DJ; Vickers SJ; Ramani P; Redfern D; Morland BJ
    Cancer Genet Cytogenet; 2001 Oct; 130(2):133-40. PubMed ID: 11675134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of heterozygosity for chromosome 14q in neuroblastoma.
    Thompson PM; Seifried BA; Kyemba SK; Jensen SJ; Guo C; Maris JM; Brodeur GM; Stram DO; Seeger RC; Gerbing R; Matthay KK; Matise TC; White PS
    Med Pediatr Oncol; 2001 Jan; 36(1):28-31. PubMed ID: 11464899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An increased NM23H1 copy number may be a poor prognostic factor independent of LOH on 1p in neuroblastomas.
    Takeda O; Handa M; Uehara T; Maseki N; Sakashita A; Sakurai M; Kanda N; Arai Y; Kaneko Y
    Br J Cancer; 1996 Nov; 74(10):1620-6. PubMed ID: 8932344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MYCN-status in neuroblastoma: characteristics of tumours showing amplification, gain, and non-amplification.
    Spitz R; Hero B; Skowron M; Ernestus K; Berthold F
    Eur J Cancer; 2004 Dec; 40(18):2753-9. PubMed ID: 15571958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of heterozygosity for chromosomes 1 or 14 defines subsets of advanced neuroblastomas.
    Fong CT; White PS; Peterson K; Sapienza C; Cavenee WK; Kern SE; Vogelstein B; Cantor AB; Look AT; Brodeur GM
    Cancer Res; 1992 Apr; 52(7):1780-5. PubMed ID: 1551108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss in chromosome 11q identifies tumors with increased risk for metastatic relapses in localized and 4S neuroblastoma.
    Spitz R; Hero B; Simon T; Berthold F
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3368-73. PubMed ID: 16740759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evolution of unbalanced gain of distal chromosome 2p in neuroblastoma.
    Stallings RL; Carty P; McArdle L; Mullarkey M; McDermott M; O'Meara A; Ryan E; Catchpoole D; Breatnach F
    Cytogenet Genome Res; 2004; 106(1):49-54. PubMed ID: 15218241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Age Dependency of the Prognostic Impact of Tumor Genomics in Localized Resectable
    Ambros IM; Tonini GP; Pötschger U; Gross N; Mosseri V; Beiske K; Berbegall AP; Bénard J; Bown N; Caron H; Combaret V; Couturier J; Defferrari R; Delattre O; Jeison M; Kogner P; Lunec J; Marques B; Martinsson T; Mazzocco K; Noguera R; Schleiermacher G; Valent A; Van Roy N; Villamon E; Janousek D; Pribill I; Glogova E; Attiyeh EF; Hogarty MD; Monclair TF; Holmes K; Valteau-Couanet D; Castel V; Tweddle DA; Park JR; Cohn S; Ladenstein R; Beck-Popovic M; De Bernardi B; Michon J; Pearson ADJ; Ambros PF
    J Clin Oncol; 2020 Nov; 38(31):3685-3697. PubMed ID: 32903140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chromosome 1p and 11q deletions and outcome in neuroblastoma.
    Attiyeh EF; London WB; Mossé YP; Wang Q; Winter C; Khazi D; McGrady PW; Seeger RC; Look AT; Shimada H; Brodeur GM; Cohn SL; Matthay KK; Maris JM;
    N Engl J Med; 2005 Nov; 353(21):2243-53. PubMed ID: 16306521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative real-time PCR for quick simultaneous determination of therapy-stratifying markers MYCN amplification, deletion 1p and 11q.
    Boensch M; Oberthuer A; Fischer M; Skowron M; Oestreich J; Berthold F; Spitz R
    Diagn Mol Pathol; 2005 Sep; 14(3):177-82. PubMed ID: 16106200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multilocus loss of heterozygosity allelotypes identify a genetic pathway associated with progression from low to high stage disease in neuroblastoma.
    Chughtai SA; Genus T; Ramani P; Dyer S; Powell JE; McMullan D; Davison V; McConville CM;
    Eur J Cancer; 2006 Aug; 42(12):1826-34. PubMed ID: 16872824
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of heterozygosity at 1p36 independently predicts for disease progression but not decreased overall survival probability in neuroblastoma patients: a Children's Cancer Group study.
    Maris JM; Weiss MJ; Guo C; Gerbing RB; Stram DO; White PS; Hogarty MD; Sulman EP; Thompson PM; Lukens JN; Matthay KK; Seeger RC; Brodeur GM
    J Clin Oncol; 2000 May; 18(9):1888-99. PubMed ID: 10784629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deletions in chromosome arms 3p and 11q are new prognostic markers in localized and 4s neuroblastoma.
    Spitz R; Hero B; Ernestus K; Berthold F
    Clin Cancer Res; 2003 Jan; 9(1):52-8. PubMed ID: 12538451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrated genomic profiling identifies two distinct molecular subtypes with divergent outcome in neuroblastoma with loss of chromosome 11q.
    Fischer M; Bauer T; Oberthür A; Hero B; Theissen J; Ehrich M; Spitz R; Eils R; Westermann F; Brors B; König R; Berthold F
    Oncogene; 2010 Feb; 29(6):865-75. PubMed ID: 19901960
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.